Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 136 of 136 entries
Sorted by: Best Match Show Resources per page
Endovascular entry closure of a late type A aortic dissection after implantation of a self-expanding transcatheter heart valve (Evolut R): a case report.

European heart journal. Case reports

Brinkmann C, Koeppel T, Schofer J.
PMID: 34557637
Eur Heart J Case Rep. 2021 Aug 18;5(9):ytab343. doi: 10.1093/ehjcr/ytab343. eCollection 2021 Sep.

BACKGROUND: Late Stanford type A aortic dissections (TAADs) are a very rare complication after transcatheter aortic valve implantation (TAVI). Surgery is the treatment of choice, but perioperative mortality (25%) and neurological complications (18%) remain high.CASE SUMMARY: An 85-year-old male...

Cite
Brinkmann C, Koeppel T, Schofer J. Endovascular entry closure of a late type A aortic dissection after implantation of a self-expanding transcatheter heart valve (Evolut R): a case report. Eur Heart J Case Rep. 2021;5(9):ytab343doi: 10.1093/ehjcr/ytab343.
Brinkmann, C., Koeppel, T., & Schofer, J. (2021). Endovascular entry closure of a late type A aortic dissection after implantation of a self-expanding transcatheter heart valve (Evolut R): a case report. European heart journal. Case reports, 5(9), ytab343. https://doi.org/10.1093/ehjcr/ytab343
Brinkmann, Christina, et al. "Endovascular entry closure of a late type A aortic dissection after implantation of a self-expanding transcatheter heart valve (Evolut R): a case report." European heart journal. Case reports vol. 5,9 (2021): ytab343. doi: https://doi.org/10.1093/ehjcr/ytab343
Brinkmann C, Koeppel T, Schofer J. Endovascular entry closure of a late type A aortic dissection after implantation of a self-expanding transcatheter heart valve (Evolut R): a case report. Eur Heart J Case Rep. 2021 Aug 18;5(9):ytab343. doi: 10.1093/ehjcr/ytab343. eCollection 2021 Sep. PMID: 34557637; PMCID: PMC8453414.
Copy Download .nbib Format: NLM
Comparison of sagittal vertical axis and decompression on the clinical outcome of cervical spondylotic myelopathy.

Clinical neurology and neurosurgery

Koeppen D, Stelling H, Goll M, Kroppenstedt S, Cabraja M.
PMID: 35030419
Clin Neurol Neurosurg. 2022 Jan 10;213:107125. doi: 10.1016/j.clineuro.2022.107125. Epub 2022 Jan 10.

OBJECTIVE: Decompression and cervical balance are major goals in the surgical treatment of cervical spondylotic myelopathy (CSM). Cervical balance is assumed to be a key factor for neurological recovery and pain reduction. Surgical reduction of C2-7 sagittal vertical axis...

Cite
Koeppen D, Stelling H, Goll M, et al. Comparison of sagittal vertical axis and decompression on the clinical outcome of cervical spondylotic myelopathy. Clin Neurol Neurosurg. 2022;213:107125doi: 10.1016/j.clineuro.2022.107125.
Koeppen, D., Stelling, H., Goll, M., Kroppenstedt, S., & Cabraja, M. (2022). Comparison of sagittal vertical axis and decompression on the clinical outcome of cervical spondylotic myelopathy. Clinical neurology and neurosurgery, 213107125. https://doi.org/10.1016/j.clineuro.2022.107125
Koeppen, Daniel, et al. "Comparison of sagittal vertical axis and decompression on the clinical outcome of cervical spondylotic myelopathy." Clinical neurology and neurosurgery vol. 213 (2022): 107125. doi: https://doi.org/10.1016/j.clineuro.2022.107125
Koeppen D, Stelling H, Goll M, Kroppenstedt S, Cabraja M. Comparison of sagittal vertical axis and decompression on the clinical outcome of cervical spondylotic myelopathy. Clin Neurol Neurosurg. 2022 Jan 10;213:107125. doi: 10.1016/j.clineuro.2022.107125. Epub 2022 Jan 10. PMID: 35030419.
Copy Download .nbib Format: NLM
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

Clinical lung cancer

Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, Zou W, Bhatia N, Koeppen H, Paul SM, Shames D, Yi J, Matheny C, Ballinger M, McCleland M, Gandara DR.
PMID: 34226144
Clin Lung Cancer. 2022 Jan;23(1):21-33. doi: 10.1016/j.cllc.2021.05.007. Epub 2021 May 30.

BACKGROUND: This phase III OAK trial (NCT02008227) subgroup analysis (data cutoff, January 9, 2019) evaluated the predictive value of 2 PD-L1 IHC tests (VENTANA SP142 and Dako 22C3) for benefit from atezolizumab versus docetaxel by programmed death ligand 1...

Cite
Gadgeel S, Hirsch FR, Kerr K, et al. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clin Lung Cancer. 2021;23(1):21-33doi: 10.1016/j.cllc.2021.05.007.
Gadgeel, S., Hirsch, F. R., Kerr, K., Barlesi, F., Park, K., Rittmeyer, A., Zou, W., Bhatia, N., Koeppen, H., Paul, S. M., Shames, D., Yi, J., Matheny, C., Ballinger, M., McCleland, M., & Gandara, D. R. (2022). Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical lung cancer, 23(1), 21-33. https://doi.org/10.1016/j.cllc.2021.05.007
Gadgeel, Shirish, et al. "Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial." Clinical lung cancer vol. 23,1 (2022): 21-33. doi: https://doi.org/10.1016/j.cllc.2021.05.007
Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, Zou W, Bhatia N, Koeppen H, Paul SM, Shames D, Yi J, Matheny C, Ballinger M, McCleland M, Gandara DR. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clin Lung Cancer. 2022 Jan;23(1):21-33. doi: 10.1016/j.cllc.2021.05.007. Epub 2021 May 30. PMID: 34226144.
Copy Download .nbib Format: NLM
Resequencing of candidate genes for Keratoconus reveals a role for Ehlers-Danlos Syndrome genes.

European journal of human genetics : EJHG

Fransen E, Valgaeren H, Janssens K, Sommen M, De Ridder R, Vandeweyer G, Bisceglia L, Soler V, Hoischen A, Mortier G, Malecaze F, Koppen C, Van Camp G.
PMID: 33737726
Eur J Hum Genet. 2021 Dec;29(12):1745-1755. doi: 10.1038/s41431-021-00849-2. Epub 2021 Mar 19.

The involvement of genetic factors in the pathogenesis of KC has long been recognized but the identification of variants affecting the underlying protein functions has been challenging. In this study, we selected 34 candidate genes for KC based on...

Cite
Fransen E, Valgaeren H, Janssens K, et al. Resequencing of candidate genes for Keratoconus reveals a role for Ehlers-Danlos Syndrome genes. Eur J Hum Genet. 2021;29(12):1745-1755doi: 10.1038/s41431-021-00849-2.
Fransen, E., Valgaeren, H., Janssens, K., Sommen, M., De Ridder, R., Vandeweyer, G., Bisceglia, L., Soler, V., Hoischen, A., Mortier, G., Malecaze, F., Koppen, C., & Van Camp, G. (2021). Resequencing of candidate genes for Keratoconus reveals a role for Ehlers-Danlos Syndrome genes. European journal of human genetics : EJHG, 29(12), 1745-1755. https://doi.org/10.1038/s41431-021-00849-2
Fransen, Erik, et al. "Resequencing of candidate genes for Keratoconus reveals a role for Ehlers-Danlos Syndrome genes." European journal of human genetics : EJHG vol. 29,12 (2021): 1745-1755. doi: https://doi.org/10.1038/s41431-021-00849-2
Fransen E, Valgaeren H, Janssens K, Sommen M, De Ridder R, Vandeweyer G, Bisceglia L, Soler V, Hoischen A, Mortier G, Malecaze F, Koppen C, Van Camp G. Resequencing of candidate genes for Keratoconus reveals a role for Ehlers-Danlos Syndrome genes. Eur J Hum Genet. 2021 Dec;29(12):1745-1755. doi: 10.1038/s41431-021-00849-2. Epub 2021 Mar 19. PMID: 33737726; PMCID: PMC8633318.
Copy Download .nbib Format: NLM
Showing 133 to 136 of 136 entries